A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the ... (NCT06335173)

ALTITUDE-AD: Sabirnetug (ALZ-201) Phase 2 Trial in Early Alzheimer's Disease

Overview

ALTITUDE-AD (NCT06335173) is a Phase 2 double-blind, randomized, placebo-controlled clinical trial evaluating the efficacy and safety of intravenous Sabirnetug (also known as ALZ-201) in patients with early Alzheimer's disease. Sponsored by Acumen Pharmaceuticals, this trial represents a critical step in developing novel disease-modifying therapies targeting amyloid-beta pathophysiology.

Sabirnetug is a monoclonal antibody designed to selectively target and neutralize toxic amyloid-beta oligomers, which are widely recognized as the primary drivers of synaptic dysfunction and neurodegeneration in AD[@aby2020]. Unlike earlier antibody approaches that focused primarily on monomeric Aβ or plaque removal, Sabirnetug specifically targets the soluble, synaptotoxic oligomeric species believed to be most pathogenic.

This Phase 2 trial builds upon earlier preclinical work demonstrating that ALZ-201 effectively reduces Aβ oligomer-induced synaptic damage in cellular and animal models. The selection of the integrated Alzheimer's Disease Rating Scale (iADRS) as the primary endpoint reflects the growing recognition that composite cognitive-functional measures capture clinically meaningful treatment effects more sensitively than individual cognitive scales alone.

Trial Details

ALTITUDE-AD: Sabirnetug (ALZ-201) Phase 2 Trial in Early Alzheimer's Disease

Overview

ALTITUDE-AD (NCT06335173) is a Phase 2 double-blind, randomized, placebo-controlled clinical trial evaluating the efficacy and safety of intravenous Sabirnetug (also known as ALZ-201) in patients with early Alzheimer's disease. Sponsored by Acumen Pharmaceuticals, this trial represents a critical step in developing novel disease-modifying therapies targeting amyloid-beta pathophysiology.

Sabirnetug is a monoclonal antibody designed to selectively target and neutralize toxic amyloid-beta oligomers, which are widely recognized as the primary drivers of synaptic dysfunction and neurodegeneration in AD[@aby2020]. Unlike earlier antibody approaches that focused primarily on monomeric Aβ or plaque removal, Sabirnetug specifically targets the soluble, synaptotoxic oligomeric species believed to be most pathogenic.

This Phase 2 trial builds upon earlier preclinical work demonstrating that ALZ-201 effectively reduces Aβ oligomer-induced synaptic damage in cellular and animal models. The selection of the integrated Alzheimer's Disease Rating Scale (iADRS) as the primary endpoint reflects the growing recognition that composite cognitive-functional measures capture clinically meaningful treatment effects more sensitively than individual cognitive scales alone.

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06335173 |
| Phase | PHASE2 |
| Status | ACTIVE_NOT_RECRUITING |
| Sponsor | Acumen Pharmaceuticals |
| Enrollment | 542 participants |
| Enrollment Type | ACTUAL |
| Study Type | INTERVENTIONAL |
| Start Date | 2024-02-29 00:00:00 |
| Completion Date | 2026-10-01 00:00:00 |
| Last Updated | 2025-10-27 00:00:00 |

Conditions Studied

• Alzheimer Disease (Early Stage, including MCI due to AD and mild AD dementia)

Mechanism of Action

Targeting Toxic Amyloid-Beta Oligomers

Sabirnetug (ALZ-201) represents a next-generation therapeutic approach that specifically targets the soluble amyloid-beta oligomeric species that are now recognized as the most synaptotoxic form of Aβ in AD pathogenesis.

Pathological Rationale:

• Amyloid-beta monomers are naturally occurring peptides that, in healthy brains, are cleared efficiently
• Aβ oligomers form when Aβ peptides aggregate into soluble, diffusible species containing 2-50 monomers
• Plaques (insoluble Aβ deposits) may actually serve as a "sink" for toxic oligomers, and their removal without targeting oligomers directly may provide limited clinical benefit

• Synaptic dysfunction and loss
• Dendritic spine degeneration
• Impaired long-term potentiation (LTP)
• Neuroinflammation through microglial activation
• Progressive cognitive decline[@aby2020]

Antibody Design and Specificity

Sabirnetug is designed to:

This selective targeting approach differs from earlier-generation anti-Aβ antibodies like aducanumab and lecanemab, which primarily target plaque amyloid with varying degrees of efficacy.

Amyloid Cascade in AD Pathogenesis

The amyloid cascade hypothesis, first proposed in 1992 and subsequently refined, posits that Aβ accumulation is the initiating event in AD pathogenesis:

However, the failure of multiple Abeta-targeting therapies has led to significant reappraisal of this model, with current understanding emphasizing:

• Abeta as necessary but not sufficient for disease
• Multiple upstream triggers (genetic, environmental, aging-related)
• Complex interactions between Abeta, tau, and neuroinflammation["@amyloid2023"]

Study Design Details

Trial Structure

This is a Phase 2, randomized, double-blind, placebo-controlled clinical trial with the following key features:

| Design Element | Description |
|---------------|-------------|
| Randomization | 1:1:1 to two active dose cohorts or placebo |
| Duration | 78 weeks (approximately 18 months) |
| Blinding | Double-blind (participant and investigator) |
| Setting | Multi-center, international |
| Phase | Phase 2 |

Treatment Arms

The trial evaluates multiple dose levels to establish:

• Dose-response relationship for efficacy
• Safety and tolerability across dose range
• Pharmacodynamic markers of target engagement
• Optimal dosing regimen for Phase 3

Primary Endpoint

Integrated Alzheimer's Disease Rating Scale (iADRS):

• Composite measure combining:
• ADAS-Cog14 (cognitive subscale, 14 items) - assesses memory, language, praxis
• ADCS-iADL (functional subscale) - assesses daily living activities
• Range: 0-146 (lower = worse function)
• Designed to capture both cognitive and functional domains in a single sensitive measure
• Previously validated in trials of early AD populations

Secondary Endpoints

Secondary endpoints likely include:

• Amyloid PET (Centiloid reduction) - measure of Aβ plaque burden
• CSF biomarkers - Aβ42/40 ratio, tau, p-tau levels
• Clinical measures - MMSE, CDR-SB
• Safety - adverse events, SAEs, immunogenicity

Eligibility Criteria

Inclusion Criteria (Anticipated)

Disease-related:

• Age 50-85 years
• Clinical diagnosis of MCI due to AD or mild AD dementia
• MMSE score 20-30 (or equivalent)
• Confirmed amyloid positivity (PET or CSF)

• Stable background medications for >4 weeks
• Adequate caregiver/support person availability
• Ability to comply with protocol requirements

Key Exclusion Criteria

• Neurological: Stroke, significant vascular disease, other dementia types
• Psychiatric: Severe depression, psychosis, active suicidal ideation
• Medical: Uncontrolled hypertension, diabetes, cardiac disease
• Medications: Current anti-Aβ therapy, immunomodulatory agents

Scientific Background

Disease Context

Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60-80% of all dementia cases. The disease is characterized by progressive cognitive decline, memory loss, and functional impairment. Pathologically, AD is associated with the accumulation of [amyloid-beta](/proteins/amyloid-beta) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain[@alzheimers2023].

The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis, proposing that accumulation of amyloid-beta peptide triggers a cascade of events leading to synaptic loss, neuronal death, and cognitive decline. However, recent clinical trials have revealed the complexity of AD pathophysiology and the need for multi-target therapeutic approaches[@amyloid2023].

Neuroinflammation in AD

A key component of AD pathophysiology that Sabirnetug may address through indirect effects on oligomer-mediated microglial activation:

The innate immune system plays a critical role in AD pathogenesis, with microglia and astrocytes contributing to both protective and pathogenic processes:

• Pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) are elevated in AD brain and correlate with disease severity
• Microglial morphometry shows disease-associated changes in density and distribution around plaques
• Complement system activation contributes to synaptic elimination
• Aβ oligomers directly activate microglia through pattern recognition receptors[@tnp2022]

Clinical Significance

Advancing the Anti-Aβ Pipeline

This trial represents one of several ongoing efforts to develop effective Aβ-targeted therapies:

| Agent | Company | Target | Stage | Key Differentiator |
|-------|---------|--------|-------|-------------------|
| Lecanemab | Eisai/Biogen | Aβ protofibrils | Approved | Early approval, confirmatory trial |
| Donanemab | Eli Lilly | N-terminal Aβ | Approved | Tartrate, staged dosing |
| Remternetug | Eli Lilly | Aβ oligomers | Phase 3 | Subcutaneous administration |
| Sabirnetug | Acumen | Aβ oligomers | Phase 2 | Selective oligomer targeting |

Challenges in AD Drug Development

The field has learned important lessons from previous Aβ antibody trials:

Implications for AD Treatment

If successful, Sabirnetug would:

Participating Sites

The trial is being conducted at multiple centers worldwide, including sites in:

• California, United States (multiple locations including Carlsbad, Fullerton, Irvine, Long Beach, Santa Ana)
• Additional international locations (specific sites to be confirmed)

Related Resources

• [Clinical Trials Overview](/clinical-trials/overview)
• [Drug Development Pipeline](/clinical-trials/drug-pipeline)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyloid Beta](/proteins/amyloid-beta)
• [Tau Protein](/proteins/tau)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
• [Neuroinflammation in AD](/mechanisms/neuroinflammation-ad)

Safety and Tolerability Considerations

Amyloid-Related Imaging Abnormalities (ARIA)

All anti-Aβ antibodies carry the risk of amyloid-related imaging abnormalities (ARIA), a class of imaging findings that include:

ARIA-E (Edema):

• Characterized by hyperintense signal on FLAIR MRI
• Represents vasogenic edema or sulcal effusions
• Typically reversible upon drug discontinuation
• Risk factors include ApoE ε4 carrier status, higher dosing

• Includes cerebral microhemorrhages, hemosiderosis
• May occur with or without ARIA-E
• Generally asymptomatic but requires monitoring

• Baseline MRI before first dose
• MRI at Week 12, Week 24, and as clinically indicated
• Careful monitoring for symptoms (headache, confusion, visual changes)
• Dose adjustment guidelines based on ARIA severity

Immunogenicity

As a monoclonal antibody, Sabirnetug may elicit anti-drug antibodies (ADAs):

• ADAs could affect PK/PD and reduce efficacy
• Potential for infusion reactions
• Long-term immunogenicity monitoring in extension studies

Comparison with Approved Aβ Antibodies

| Parameter | Lecanemab | Donanemab | Sabirnetug |
|-----------|-----------|-----------|------------|
| Target | Protofibrils | N-terminal | Oligomers |
| Dosing | Q2W IV | Q4W IV | TBD |
| ARIA-E rate | ~10% | ~24% | TBD |
| ARIA-H rate | ~17% | ~31% | TBD |
| Infusion time | 60 min | 60 min | TBD |

Competitive Landscape and Market Context

AD Treatment Market

The Alzheimer's disease treatment market represents one of the largest unmet medical needs:

• Global AD population: ~55 million (2023)
• Projected to reach 139 million by 2050
• Market for disease-modifying therapies: >$10B annually

Key Players and Pipeline

Eisai/Biogen (Lecanemab/Leqembi):

• First disease-modifying AD therapy (2023 approval)
• Confirmatory Phase 4 trial ongoing
• Subcutaneous formulation in development

• Approved November 2024
• Requires tau confirmation for use
• Phase 4 real-world evidence program

• Next-generation oligomer-targeting antibody
• Phase 3 TRAILBLAZER-ALZ 6
• Subcutaneous administration

• Differentiated oligomer-selective mechanism
• Phase 2 ALTITUDE-AD in progress
• Potential for earlier-stage intervention

Strategic Considerations

Acumen's approach with Sabirnetug reflects several strategic decisions:

Pharmacological Considerations

Pharmacokinetics

Monoclonal antibodies like Sabirnetug exhibit distinct PK properties:

• Distribution: Limited to vascular compartment; slow distribution into CNS
• Half-life: Extended half-life (~21-28 days) supports less frequent dosing
• Clearance: Fc-mediated clearance; may be affected by target burden
• CSF penetration: Low (~0.1-1% of plasma exposure)

Pharmacodynamics

Expected PD effects include:

• Reduced plasma Aβ oligomer levels
• Decreased CSF Aβ42 (reflecting brain clearance)
• Potential for downstream tau effects
• Biomarker changes prior to clinical effects

Biomarker Strategy

Comprehensive biomarker program to understand:

• Amyloid PET - Plaque burden change
• CSF Aβ42/40 - Shift toward normalization
• CSF tau/p-tau - Disease progression markers
• Neurofilament light (NfL) - Neurodegeneration marker
• Neuroinflammation markers - Microglial activation status

Future Directions

Potential for Combination Therapy

Given the complex pathophysiology of AD, combination approaches may provide enhanced benefit:

Rationale for combinations:

• Multiple pathways involved in disease
• Synergistic effects possible
• May allow lower doses with maintained efficacy

• Aβ antibody + anti-tau therapy
• Aβ antibody + neuroinflammation modulator
• Aβ antibody + symptomatic agents

Personalized Medicine Approaches

Future development may incorporate:

• ApoE genotype - Tailored dosing/safety monitoring
• Biomarker profiles - Patient selection based on pathology
• Genetic risk scores - Early intervention in high-risk individuals
• Digital biomarkers - Remote monitoring of treatment response

Expansion to Preclinical AD

If Phase 2/3 trials successful, potential expansion to:

• Preclinical AD (cognitively normal, biomarker positive)
• Combination prevention studies
• Early genetic forms of AD (autosomal dominant)

Clinical Trial Design Innovations

Master Protocol Approach

While ALTITUDE-AD is a traditional RCT design, the broader AD field is moving toward innovative trial designs:

Platform Trials:

• Multiple treatments tested simultaneously
• Shared control group improves efficiency
• Adaptive randomization based on interim results
• Example: Alzheimer's Disease Tau Platform (NCT06957418)

• Group patients by biomarker rather than diagnosis
• Pathology-driven patient selection
• Efficient for rare subtypes

• Multiple subtypes within single disease
• Biomarker-stratified assignment to arms
• Personalized medicine approach

Decentralized Trial Elements

Modern AD trials increasingly incorporate remote/digital elements:

• Telehealth visits for safety monitoring
• Digital cognitive assessments (e.g., Cambridge Neuropsychological Test Automated Battery)
• Wearable devices for activity/motor monitoring
• At-home MRI for ARIA monitoring (emerging)
• Electronic patient-reported outcomes (ePRO)

Enrichment Strategies

Successful trials in AD have employed enrichment:

• Biomarker enrichment - Amyloid-positive confirmed via PET or CSF
• Stage enrichment - Early AD (MCI-mild dementia)
• Genetic enrichment - ApoE ε4 carriers for higher risk
• Compliance enrichment - Prior trial experience

Regulatory Context and Development Pathway

Accelerated Approval Pathway

Anti-Aβ antibodies have received accelerated approval based on amyloid reduction:

• Lecanemab - Accelerated approval 2023, full approval 2024
• Donanemab - Accelerated approval 2024

• Clinical benefit confirmation in post-marketing studies
• Continued safety monitoring
• Real-world effectiveness data

FDA Guidance for AD Trials

The FDA has issued guidance for AD drug development:

• Early AD population recommended for disease-modifying trials
• Composite endpoints (iADRS, CDR-SB) preferred
• Biomarker validation encouraged but not required
• Confirmatory trial required for accelerated approval

EMA Considerations

European Medicines Agency perspective:

• Emphasizes clinical relevance over biomarker endpoints
• More conservative on ARIA risk acceptance
• Requires robust clinical outcomes for approval

Global Harmonization

ICH guidelines support international trial conduct:

• Harmonized inclusion/exclusion across regions
• Consistent endpoint assessment methodology
• Regulatory convergence for approval decisions

Summary and Key Takeaways

ALTITUDE-AD (NCT06335173) represents a significant advancement in Alzheimer's disease drug development:

Key facts:

• Enrollment: 542 participants
• Status: Active, not recruiting
• Timeline: 2024-2026
• Primary endpoint: iADRS change at Week 78
• Sponsor: Acumen Pharmaceuticals

Trial Identifier: NCT06335173 Official Title: A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) Alternate Title: ALTITUDE-AD

External Links

• [ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT06335173)
• [PubMed Search](https://pubmed.ncbi.nlm.nih.gov/?term=NCT06335173)

References